Advanced primary peritoneal carcinoma: clinicopathological and prognostic factor analyses
- 37 Downloads
To investigate the factors favoring a positive prognosis for advanced primary peritoneal carcinoma (PPC).
Twenty-four cases meeting the criteria for PPC were analyzed retrospectively for the clinicopathologic profiles. Immunohistochemistry was used to determine the expressions of p53, Top2α, Ki-67 and Her-2/neu. Then all these clinicopathological factors and molecular markers were correlated with the prognosis.
There were 15 cases of primary peritoneal serous papillary carcinoma (PPSPC), 6 cases of mixed epithelial carcinoma (MEC) and 3 cases of malignant mixed Mullerian tumor (MMMT). All patients underwent cytoreductive surgery with optimal debulking achieved in 3 cases. Among those receiving first-line chemotherapy, 13 patients received the TP regimen (paclitaxel-cisplatin or carboplatin) and 7 patients received the PAC regimen (cisplatin-doxorubicin-cyclophosphamide). The median overall survival of all patients was 42 months, while the breakdown for survival time for patients with PPSPC, MMT and MEC was 44, 13 and 19 months, respectively. The expressions of p53, Top2α and Ki-67 were all demonstrated in 11 cases respectively. None showed the expression of Her-2/neu. There were significant differences in the median survival between patients with PPSPC and those with MMMT (44 months vs 13 months, P<0.05), also between patients receiving TP combination and those receiving the PAC regimen (75 months vs 28 months, P<0.05). Another significant difference in the median progression-free survival (PFS) was identified between patients with positive p53 immunostaining and those with negative p53 immunostaining (15 months vs 47 months, P<0.05), whereas age, menopausal status, residual tumor size and the other molecular factors did not significantly impact survival.
Patients with PPC should be treated with a comprehensive management plan including appropriate cytoreductive surgery and responsive chemotherapy. Overestimating an optimal debulking surgery may not benefit survival. The pathologic subtype, chemotherapy regimen and p53 overexpression were significant prognostic factors.
Key wordsPrimary peritoneal carcinoma (PPC) Cytoreductive surgery Chemotherapy Immunohistochemistry Prognosis
CLC numberR711 R737
Unable to display preview. Download preview PDF.
- Ben-Baruch, G., Sivan, E., Moran, O., Rizel, S., Menczer, J., Seidman, D.S., 1996. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III–IV ovarian papillary serous carcinoma. Gynecol. Oncol., 60(3):393–396. [doi:10.1006/gyno.1996.0060]PubMedCrossRefGoogle Scholar
- Bloss, J.D., Liao, S.Y., Buller, R.E., Manetta, A., Berman, M.L., McMeekin, S., Bloss, L.P., DiSaia, P.J., 1993. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol. Oncol., 50(3):347–351. [doi:10.1006/gyno.1993.1223]PubMedCrossRefGoogle Scholar
- Bloss, J.D., Brady, M.F., Liao, S.Y., Rocereto, T., Partridge, E.E., Clarke-Pearson, D.L., Gynecologic Oncology Group Study, 2003. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with paillary serous ovarian carcinoma. Gynecol. Oncol., 89(1):148–154. [doi:10.1016/S0090-8258(03)00068-4]PubMedCrossRefGoogle Scholar
- Garamvoelgyi, E., Guillou, L., Gebhard, S., Salmeron, M., Seematter, R.J., Hadji, M.H., 1994. Primary malignant mixed mullerian tumor (metaplastic carcinoma) of the female peritoneum: a clinical, pathologic and immunohistochemical study of three cases and a review of the literature. Cancer, 74(3):854–863. [doi:10.1002/1097-0142(19940801)74:3〈854::AID-CNCR2820740311〉3.0.CO;2-R]PubMedCrossRefGoogle Scholar
- Kowalski, L.D., Kanbour, A.I., Price, F.V., Finkelstein, S.D., Christopherson, W.A., Seski, J.C., Naus, G.J., Burnham, J.A., Kanbour-Shakir, A., Edwards, R.P., 1997. A casematched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer, 79(8):1587–1594. [doi:10.1002/(SICI)1097-0142(19970415)79:8〈1587::AID-CNCR22〉3.0.CO;2-T]PubMedCrossRefGoogle Scholar
- Piver, M.S., Eltabbakh, G.H., Hempling, R.E., Recio, F.O., Blumenson, L.E., 1997. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin. Gynecol. Oncol., 67(2):141–146. [doi:10.1006/gyno.1997.4843]PubMedCrossRefGoogle Scholar
- Shen, D.H., Khoo, U.S., Xue, W.C., Ngan, H.Y., Wang, J.L., Liu, V.W., Chan, Y.K., Cheung, A.N., 2001. Primary peritoneal malignant mixed Mullerian tumors. A clinicopathologic, immunohistochemical and genetic study. Cancer, 91(5):1052–1060. [doi:10.1002/1097-0142(20010301)91:5〈1052::AID-CNCR1097〉3.3.CO;2-1]PubMedCrossRefGoogle Scholar